Showing 4121-4130 of 9578 results for "".
- Network Meta-analysis: Oral Isotretinoin Is the Most Effective Acne Treatmenthttps://practicaldermatology.com/news/network-meta-analysis-oral-isotretinoin-is-the-most-effective-acne-treatment/2461888/Oral isotretinoin, followed by topical antibiotic, benzoyl peroxide and retinoid, are most effective acne treatments, according to a network meta-analysis of 221 randomized controlled trials. For the study, researchers investigated the effectiveness of various pharmacological
- LRP Celebrates Acne Positivity with Two-Day 'Positivity Lab' Pop-Up Experience in NYChttps://practicaldermatology.com/news/lrp-celebrates-acne-positivity-with-two-day-positivity-lab-pop-up-experience-in-nyc/2461879/La Roche-Posay is hosting a consumer pop-up experience to help destigmatize acne. The pop-up will feature an immersive "Science of Skin" exhibit, a meditation lounge in partnership with obé Fitness, Doodle Bar with custom art done by local artists, and a Positivity Phot
- Almirall on Track for Net-Zero GHG emissions by 2050https://practicaldermatology.com/news/almirall-on-track-for-net-zero-ghg-emissions-by-2050/2461877/The Science-Based Targets initiative (SBTi) has validated Almirall’s Environmental, Social and Governance (ESG) targets to achieve net zero greenhouse gas (GHG) emissions across the value chain by 2050, under the 'Net-Zero Standard'. The company has als
- Enspectra Health Awarded NIH Grant to Advance Predictive Algorithms for AKshttps://practicaldermatology.com/news/enspectra-health-awarded-nih-grant-to-advance-predictive-algorithms-for-aks/2461874/Enspectra Health scored $2M in grant funding from the National Cancer Institute (NCI) to support research for developing deep learning algorithms to predict which actinic keratosis (AK) lesions, are likely to progress to squamous cell carcinoma (SCC). Enspectra's technolog
- Cetuximab Plus Radiation May Be Effective Treatment for Advanced Squamous Cell Skin Cancerhttps://practicaldermatology.com/news/cetuximab-plus-radiation-may-be-effective-treatment-for-advanced-squamous-cell-skin-cancer/2461860/Cetuximab plus radiotherapy may be an effective treatment option for locally advanced cutaneous squamous cell cancers (laCSCC), with manageable toxicity, according to a study in Oncotarget. Cetuximab is
- Opzelura Cream Safely Eases AD in Young Kidshttps://practicaldermatology.com/news/opzelura-cream-safely-eases-ad-in-young-kids/2461857/Incyte’s ruxolitinib cream (Opzelura) cleared skin in significantly more kids with atopic dermatitis (AD) than a nonmedicated topical control, a new study shows. The study, which included 300 kids aged ≥2 to <12, met its primary endpoint and showed signi
- Exosome News: ExoCoBio Completes Acquisition of Benevhttps://practicaldermatology.com/news/exosome-news-exocobio-completes-acquisition-of-benev/2461855/ExoCoBio has acquired a majority ownership in BENEV, a global medical aesthetic company that produces growth factor-based skincare products. ExoCoBio produces exosome-based regenerative aesthetics and medicine products and currently holds 54 patents and 15 scientific publicati
- WCD News: Connect Biopharma's Rademikibart Earns High Marks in ADhttps://practicaldermatology.com/news/wcd-news-connect-biopharmas-rademikibart-earns-high-marks-in-ad/2461851/Four new studies support the efficacy and safety of rademikibart in atopic dermatitis (AD), Connect Biopharma reports. Rademikibart (CBP-201), a next-generation IL-4Rα antibody, achieved all primary and secondary endpoints in a randomized pivotal trial for moderate-to-severe
- AD Pipeline Watch: Eblasakimab Monthly Dosing Shows Promise in Phase 2b AD Studyhttps://practicaldermatology.com/news/eblasakimab-monthly-dosing-shows-promise-in-phase-2b-ad-study/2461845/ASLAN Pharmaceuticals’ eblasakimab met the primary endpoint of percent change from baseline in the Eczema Area and Severity Index (EASI) score at week 16 versus placebo in adult patients with moderate-to-severe atopic dermatitis (AD), according to results from the Phase 2b dose-ra
- Biosimilar News: Another Humira Biosimilar Enters US Markethttps://practicaldermatology.com/news/biosimilar-news-another-humira-biosimilar-enters-us-market/2461835/Biocon Biologics Ltd’s HULIO (adalimumab-fkjp) injection, a biosimilar to Humira (adalimumab), is now available in the United States after five years of experience in Europe and two years in Canada. "The launch of HULIO, our biosim